Cangrelor is an intravenous P2Y12 platelet inhibitor approved to treat patients with coronary artery disease, specifically to reduce the risk of ischemic events by preventing platelet aggregation. Analytical… Read more


![Chemical structure of 2-[(3,3,3-Trifluoropropyl)thio]-adenosine](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F163706-51-2-2-333-Trifluoropropylthio-adenosine.png&w=3840&q=75)












![Chemical structure of N-[2-(Methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-adenosine (9CI)](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F163706-58-9-N-2-Methylthioethyl-2-333-trifluoropropylthio-adenosine-9CI.png&w=3840&q=75)
![Chemical structure of N-[2-(Methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-adenosine 2',3',5'-triacetate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1830294-26-2-N-2-Methylthioethyl-2-333-trifluoropropylthio-adenosine-235-triacetate.png&w=3840&q=75)
![Chemical structure of N-[2-(Methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-adenosine, 5'-(hydrogen P-1H-imidazol-1-ylphosphonate)](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F847460-53-1-N-2-Methylthioethyl-2-333-trifluoropropylthio-adenosine-5-hydrogen-P-1H-imidazol-1-ylphosphonate.png&w=3840&q=75)

Cangrelor is an intravenous P2Y12 platelet inhibitor approved to treat patients with coronary artery disease, specifically to reduce the risk of ischemic events by preventing platelet aggregation. Analytical laboratories utilize high-quality reference standards of this drug and its related compounds to maintain rigorous quality control and regulatory compliance. This category includes a comprehensive range of impurities, including degradation products, synthetic intermediates, and structural analogs essential for impurity profiling, forced degradation studies, and the optimization of analytical methods. Furthermore, stable isotope labelled compounds are available to serve as internal standards for accurate quantification during method validation. By incorporating these validated materials into routine testing, pharmaceutical researchers can ensure the consistency, safety, and efficacy of their formulations, satisfying both pharmacopeial and international regulatory requirements for the analysis of Cangrelor and its related substances.